$RARE
AI AnalysisGenerated on May 11, 2026
AI Score
Hold$RARE
Ultragenyx Pharmaceutical
$RARENASDAQHealthcareMid-Cap
Ultragenyx develops gene therapies and biologics for rare and ultra-rare diseases.
Market Cap
$4.0B
Revenue (TTM)
$0.5B
+15.0%
Net Income (TTM)
-$0.4B
N/A
EPS (TTM)
-$5.00
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$38-$65
Beta
0.72
Dimension Scores
Fundamental
40Technical
48Sentiment
55Risk / Reward
42Momentum
55Financial Health
Profitability
45weak
Growth
58moderate
Liquidity
50strong
Solvency
42moderate
Efficiency
38moderate
Valuation, technical analysis, investment thesis, risk assessment and more for $RARE
Free · No credit card required
Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.